Development of a recombinant tetravalent dengue virus vaccine: Innmunogenicity and efficacy studies in mice and monkeys

被引:155
作者
Clements, David E. [1 ]
Coller, Beth-Ann G. [1 ]
Lieberman, Michael M. [1 ]
Ogata, Steven [1 ]
Wang, Gordon [1 ]
Harada, Kent E. [1 ]
Putnak, J. Robert [2 ]
Ivy, John M. [1 ]
McDonell, Michael [1 ]
Bignami, Gary S. [1 ]
Peters, Iain D. [1 ]
Leung, Julia [1 ]
Weeks-Levy, Carolyn [1 ]
Nakano, Eileen T. [1 ]
Humphreys, Tom [1 ]
机构
[1] Hawaii Biotech Inc, Aiea, HI 96701 USA
[2] Walter Reed Army Inst Res, Silver Spring, MD 20910 USA
关键词
Dengue; Envelope; Subunit; Vaccine; ENVELOPE GLYCOPROTEIN; HEMORRHAGIC-FEVER; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; STRUCTURAL PROTEINS; DISEASE SEVERITY; STRAIN; 16681; CDNA-CLONES; CELLS; DETERMINANTS;
D O I
10.1016/j.vaccine.2010.01.022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Truncated recombinant dengue virus envelope protein subunits (80E) are efficiently expressed using the Drosophila Schneider-2 (S2) cell expression system. Binding of conformationally sensitive antibodies as well as X-ray crystal structural studies indicate that the recombinant 80E subunits are properly folded native-like proteins. Combining the 80E subunits from each of the four dengue serotypes with ISCOMATRIX (R) adjuvant, an adjuvant selected from a set of adjuvants tested for maximal and long lasting immune responses, results in high titer virus neutralizing antibody responses. Immunization of mice with a mixture of all four 80E subunits and ISCOMATRIX (R) adjuvant resulted in potent virus neutralizing antibody responses to each of the four serotypes. The responses to the components of the tetravalent mixture were equivalent to the responses to each of the subunits administered individually. In an effort to evaluate the potential protective efficacy of the Drosophila expressed 80E, the dengue serotype 2 (DEN280E) subunit was tested in both the mouse and monkey challenge models. In both models protection against viral challenge was achieved with low doses of antigen in the vaccine formulation. In non-human primates, low doses of the tetravalent formulation induced good virus neutralizing antibody titers to all four serotypes and protection against challenge with the two dengue virus serotypes tested. In contrast to previous reports, where subunit vaccine candidates have generally failed to induce potent, protective responses, native-like soluble 80E proteins expressed in the Drosophila S2 cells and administered with appropriate adjuvants are highly immunogenic and capable of eliciting protective responses in both mice and monkeys. These results support the development of a dengue virus tetravalent vaccine based on the four 80E subunits produced in the Drosophila S2 cell expression system. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2705 / 2715
页数:11
相关论文
共 65 条
[1]  
Angsubhakorn Subhkij, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P554
[2]   Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein [J].
Beasley, DWC ;
Barrett, ADT .
JOURNAL OF VIROLOGY, 2002, 76 (24) :13097-13100
[3]   Analysis of a recombinant dengue-2 virus dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system [J].
BielefeldtOhmann, H ;
Beasley, DWC ;
Fitzpatrick, DR ;
Aaskov, JG .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :2723-2733
[4]   Targeted Mutagenesis as a Rational Approach to Dengue Virus Vaccine Development [J].
Blaney, Joseph E., Jr. ;
Durbin, Anna P. ;
Murphy, Brian R. ;
Whitehead, Stephen S. .
DENGUE VIRUS, 2010, 338 :145-158
[5]   CONSTRUCTION OF INTERTYPIC CHIMERIC DENGUE VIRUSES BY SUBSTITUTION OF STRUCTURAL PROTEIN GENES [J].
BRAY, M ;
LAI, CJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10342-10346
[6]   Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge [J].
Bray, M ;
Men, RH ;
Lai, CJ .
JOURNAL OF VIROLOGY, 1996, 70 (06) :4162-4166
[7]  
Cardosa MJ, 1998, BRIT MED BULL, V54, P395, DOI 10.1093/oxfordjournals.bmb.a011696
[8]   Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting [J].
Chambers, TJ ;
Tsai, TF ;
Pervikov, Y ;
Monath, TP .
VACCINE, 1997, 15 (14) :1494-1502
[9]   Short report: Immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine [J].
Chanthavanich, Pornthep ;
Luxemburger, Christine ;
Sirivichayakul, Chukiat ;
Lapphra, Keswadee ;
Pengsaa, Krisana ;
Yoksan, Sutee ;
Sabchareon, Arunee ;
Lang, Jean .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (01) :26-28
[10]   REGULATED EXPRESSION ALLOWS HIGH-LEVEL PRODUCTION AND SECRETION OF HIV-1 GP120 ENVELOPE GLYCOPROTEIN IN DROSOPHILA SCHNEIDER CELLS [J].
CULP, JS ;
JOHANSEN, H ;
HELLMIG, B ;
BECK, J ;
MATTHEWS, TJ ;
DELERS, A ;
ROSENBERG, M .
BIO-TECHNOLOGY, 1991, 9 (02) :173-177